ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

abemaciclib

Also written as “Abemaciclib”, “LY2835219” and “Abemaciclib Tablet (Test Formulation)”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Prostatic Neoplasms · Neoplasm Metastasis · Sarcoma, Ewing, led by 2 companies.

Drug pageAbemaciclib: every studyAll 156 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 12, 201949 company-led studies, 14 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly4814 open or runningphase 4since Jun 12, 2019Jul 12, 2011Nov 2026phase 1 · NCT07818967
Hoffmann-La Rocheits history only10 open or runningphase 2since Sep 11, 2017Sep 11, 2017none ahead

Also a collaborator on its studies: Bayer and Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 34 studies since Jul 12, 2011.

  1. Jun 12, 2019Phase 4 study in Breast NeoplasmsNCT03988114 · United States, Argentina, Austria and more
  2. Jul 23, 2019Phase 4 study in Breast NeoplasmsNCT04031885 · 4 enrolled · United States, Puerto Rico
  3. Aug 26, 2019Phase 1 study in Advanced CancerNCT04071262 · 6 enrolled · Japan
  4. Jan 22, 2020Phase 2 study in Sarcoma, EwingNCT04238819 · 47 enrolled · United States, Australia, Belgium and more
  5. May 28, 2020Phase 2 study in Metastatic Castration-Resistant Prostate CancerNCT04408924 · 44 enrolled · United States, France, Spain
  6. Jan 12, 2021Phase 4 study in Breast NeoplasmsNCT04707196 · 200 enrolled · India
  7. Feb 11, 2021Phase 3 study in Breast NeoplasmsNCT04752332 · 111 enrolled · United States, Argentina, Australia and more
  8. Dec 22, 2021Phase 3 study in Breast NeoplasmsNCT05169567 · 368 enrolled · United States, Argentina, Belgium and more
  9. Mar 10, 2022Phase 3 study in Prostatic NeoplasmsNCT05288166 · 925 enrolled · United States, Argentina, Australia and more
  10. Jun 28, 2022Phase 2 study in Sarcoma, EwingNCT05440786 · 46 enrolled · United States, Australia, France and more
  11. Aug 14, 2023Phase 2 study in NeoplasmsNCT05999994 · 105 planned · United States, Australia, Belgium and more
  12. Aug 14, 2023Phase 1 study in Prostatic NeoplasmsNCT05999968 · 10 enrolled · United States, Germany, Spain
  13. May 9, 2024Phase 2 study in GliomaNCT06413706 · 45 enrolled · United States, Australia, Belgium and more
  14. Aug 26, 2026Phase 1 study in Healthy VolunteersNCT07818967 · 15 planned · Singapore

Ahead

  1. Nov 2026Primary completion: phase 1 study in Healthy VolunteersNCT07818967
  2. Feb 2027Primary completion: phase 2 study in GliomaNCT06413706
  3. May 2027Primary completion: phase 2 study in NeoplasmsNCT05999994

TargetBeta

CDK4 →CDK6 →read by rule
“The mesylate salt of abemaciclib, an orally available cyclin-dependent kinase (CDK) inhibitor that targets the cyclin D1-CDK4 and cyclin D3-CDK6 cell cycle pathway, ”NCIt, by rule
“Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
palbociclibrulePfizerphase 436
trilaciclibrulePharmacosmosphase 414
culmerciclibSino Biopharmaceuticalphase 311
narazaciclibrulehangzhou-hanx-biopharmaceuticals-ltdphase 24
vustanaciclibregor-pharmaceuticals-incphase 23

Studies

All 48 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07818967Healthy Volunteers · Singapore1RecruitingNov 202615
NCT06413706Glioma · United States, Australia, Belgium and more2Active, not recruitingFeb 202745
NCT05999994Neoplasms · United States, Australia, Belgium and more2RecruitingMay 2027105
NCT05999968Prostatic Neoplasms · United States, Germany, Spain1TerminatedFeb 23, 202410
NCT05440786Sarcoma, Ewing · United States, Australia, France and more2Active, not recruitingJan 15, 202546
NCT05288166Prostatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingFeb 15, 2024925
NCT05169567Breast Neoplasms · United States, Argentina, Belgium and more3Active, not recruitingFeb 8, 2024368
NCT04752332Breast Neoplasms · United States, Argentina, Australia and more3TerminatedJun 26, 2024111
NCT04707196Breast Neoplasms · India4CompletedJan 9, 2023200
NCT04408924Metastatic Castration-Resistant Prostate Cancer · United States, France, Spain2CompletedApr 27, 202244
NCT04238819Sarcoma, Ewing · United States, Australia, Belgium and more2CompletedMar 15, 202447
NCT04071262Advanced Cancer · Japan1CompletedFeb 12, 20216
NCT04031885Breast Neoplasms · United States, Puerto Rico4TerminatedAug 11, 20204
NCT03988114Breast Neoplasms · United States, Argentina, Austria and more4WithdrawnMar 23, 20220
NCT03703466Breast Neoplasms · Australia, Belgium, Russian Federation and more2CompletedJul 29, 201972
NCT03706365Prostatic Neoplasms · United States, Australia, China and more3Active, not recruitingJan 2, 2024393
NCT03155997Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingMar 16, 20205,637
NCT02981342Pancreatic Neoplasms · United States, Australia, Belgium and more2CompletedApr 20, 2018106
NCT02919696Neoplasm Metastasis · China1CompletedNov 23, 201826
NCT02884089Healthy · United States1CompletedDec 201640
NCT02779751Carcinoma, Non-Small-Cell Lung · United States, Belgium, France and more1Active, not recruitingFeb 3, 2020100
NCT02763566Breast Neoplasms · Brazil, China, India and more3Active, not recruitingMar 29, 2019463
NCT02747004Breast Neoplasms · United States, Argentina, Austria and more2CompletedJun 15, 2018234
NCT02745769Colorectal Neoplasms · United States, France, United Kingdom1CompletedNov 5, 201823
NCT02688088Neoplasm Metastasis · United States1CompletedFeb 4, 201848
NCT02677844Healthy · United States1CompletedJul 201635
NCT02675231Hormone Receptor Positive Breast Cancer · United States, Argentina, Australia and more2CompletedApr 8, 2019237
NCT02672423Healthy · United States1CompletedOct 2016127
NCT02482935Healthy · United States1CompletedSep 201530
NCT02450539Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more2CompletedMar 31, 2017159
NCT02441946Breast Neoplasms · United States, Austria, Belgium and more2CompletedAug 16, 2016224
NCT02411591Carcinoma, Non-Small-Cell Lung · Belgium, France, Spain1CompletedJun 23, 201766
NCT02387814Hepatic Insufficiency · United States1CompletedAug 201535
NCT02327143Healthy Volunteers · United Kingdom1CompletedFeb 201511
NCT02308020Breast Neoplasms · United States, Australia, Austria and more2CompletedNov 8, 2018162
NCT02256267Healthy Volunteers · United States1CompletedNov 201424
NCT02246621Breast Neoplasms · United States, Australia, Austria and more3Active, not recruitingJan 31, 2017493
NCT02152631Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more3Active, not recruitingSep 15, 2017453
NCT02117648Neoplasms · United States1CompletedFeb 201526
NCT02107703Breast Neoplasms · United States, Australia, Belgium and more3Active, not recruitingFeb 14, 2017669
NCT02102490Breast Neoplasms · United States, Belgium, France and more2CompletedApr 30, 2016132
NCT02079636Carcinoma, Non-Small-Cell Lung · United States, Spain1CompletedMay 2, 2018142
NCT02059148Healthy Volunteers · United States1CompletedAug 201424
NCT02057133Breast Neoplasms · United States1Active, not recruitingMar 15, 2021198
NCT02014129Neoplasm Metastasis · Japan1CompletedApr 1, 201512
NCT01913314Healthy Volunteers · United States1CompletedOct 20136
NCT01739309Lymphoma, Mantle-Cell · France, Germany2CompletedSep 28, 201528
NCT01394016Advanced Cancer · United States1CompletedMay 29, 2014225

How it is read

Names in the registry

  • “Abemaciclib”, 41 entries
  • “LY2835219”, 5 entries
  • “Abemaciclib Tablet (Test Formulation)”, 2 entries
  • “Abemaciclib Tablet (Reference Formulation)”, 1 entry
  • “Abemaciclib Oral Granules (Test Formulation)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.